Marta Medeot

Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning

Christopher G. Kanakry, Paul V. O’Donnell, Terry Furlong et al. · Journal of Clinical Oncology · 2014 · 280 citations · Full text

Medicine, Hematology, Immunology +17

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Dietrich W. Beelen, Rudolf Trenschel, Matthias Stelljes et al. · The Lancet Haematology · 2019 · 154 citations · Full text

Medicine, Hematology, Immunology +17

Low‐dose rituximab in adult patients with primary immune thrombocytopenia

Francesco Zaja, Nicola Vianelli, Stefano Volpetti et al. · European Journal Of Haematology · 2010 · 126 citations

Medicine, Hematology, Pharmacotherapy +8

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Christopher G. Kanakry, Javier Bolaños‐Meade, Yvette L. Kasamon et al. · Blood · 2017 · 90 citations · Full text

Life Sciences, Hematology, Immunology +16

Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long‐term follow‐up results

Marta Medeot, Francesco Zaja, Nicola Vianelli et al. · European Journal Of Haematology · 2008 · 78 citations · Full text

Medicine, Hematology, Pharmacotherapy +14